Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short-term Investments: 2020-2024

Historic Short-term Investments for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • Apellis Pharmaceuticals' Short-term Investments rose 4.15% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 4.15%. This contributed to the annual value of $1.3 million for FY2024, which is 18.67% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Short-term Investments of $1.3 million as of FY2024, which was up 18.67% from $1.1 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Short-term Investments high stood at $311.9 million for FY2020, and its period low was $1.1 million during FY2023.
  • Moreover, its 3-year median value for Short-term Investments was $1.3 million (2022), whereas its average is $1.2 million.
  • In the last 5 years, Apellis Pharmaceuticals' Short-term Investments plummeted by 97.89% in 2022 and then increased by 18.67% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Short-term Investments (Yearly) stood at $311.9 million in 2020, then plummeted by 80.65% to $60.4 million in 2021, then crashed by 97.89% to $1.3 million in 2022, then decreased by 12.49% to $1.1 million in 2023, then climbed by 18.67% to $1.3 million in 2024.